The results from a Phase I clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist designed to treat obesity and T2DM, showed a mean placebo-adjusted weight loss of 6.1% over four weeks [46]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.